Imaging of the prostate-specific membrane antigen (PSMA) has become an important tool for managing patients with recurrent prostate cancer, and one of the most frequently employed radiopharmaceuticals is [⁶⁸Ga]Ga-PSMA-11. Herein, we summarize the preclinical development and the clinical applications of [⁶⁸Ga]Ga-PSMA-11 and present side-by-side comparisons with other radiopharmaceuticals or imaging modalities, in order to assist imagers and clinicians in recommending, performing, and interpreting the results of [⁶⁸Ga]Ga-PSMA-11 PET scans in patients with prostate cancer.